Table 1. General characteristics and laboratory data of study subjects.
| Initial (n = 140) | Follow-up (n = 140) | P | |
| Age (year) | 56.6±9.8 | 58.5±9.8 | |
| Sex (M/F) | 72/68 | 72/68 | |
| DM duration (month) | 86.0±71.2 | 110.1±71.2 | |
| SBP (mm Hg) | 136.0±14.3 | 133.8±16.9 | |
| DBP (mm Hg) | 75.1±8.9 | 77.6±9.4 | |
| BMI (kg/m2) | 27.6±4.5 | 27.7±6.8 | |
| Fasting sugar (mg/dl) | 150.1±47.9 | 149.8±45.5 | |
| HbA1c (%) | 7.8±1.6 | 7.8±1.4 | |
| Total cholesterol (mg/dl) | 178.1±38.6 | 173.0±36.0 | |
| Triglyceride (mg/dl) | 181.1±134.4 | 188.8±161.7 | |
| HDL (mg/dl) | 39.9±11.6 | 41.7±12.2 | |
| LDL (mg/dl) | 102.7±39.2 | 98.0±28.5 | |
| HS-CRP (mg/dl) | 2.8±6.6 | 3.1±6.4 | |
| BUN (mg/dl) | 17.4±8.8 | 18.5±11.6 | |
| Creatinine (mg/dl) | 1.2±1.4 | 1.4±1.3 | |
| eGFR (ml/min/1.73 m2) | 86.4±31.1 | 74.4±27.3 | <0.001 |
| Urine albumin (mg/day) | 264.9±1060.3 | 557.7±2092.5 | 0.009 |
| Serum NGAL (ng/ml) | 70.0±35.7 | 90.6±55.6 | 0.001 |
| Serum L-FABP (pg/ml) | 6810.3±5450.5 | 7657.7±4733.2 | |
| Urine NGAL (ng/ml) | 18.3±58.2 | 23.3±21.0 | |
| Urine L-FABP (pg/ml) | 7431.6±13761.8 | 8445.1±11858.8 | |
| ACEIs (%) | 21.4 | 20.7 | |
| ARBs (%) | 53.6 | 66.2 | 0.003 |
| Statins (%) | 62.3 | 60.4 | |
| Eztrol (%) | 9.4 | 9.4 | |
| Fibrates (%) | 13.0 | 11.5 | |
| Insulin (%) | 18.8 | 21.8 | |
Abrreviations:
DM: diabettes mellitus.
SBP: systolic blood pressure.
DBP: diastolic blood pressure.
BMI: body mass index.
HbA1c: glycated hemoglobin.
HDL: high-density lipoprotein.
LDL: low-density lipoprotein.
HS-CRP: highly sensitive C-reactive protein.
eGFR: estimated glomerular filtration rate.
NGAL: neutrophil gelatinase-associated lipocalin.
L-FABP: liver-type fatty acid-binding protein.
ACEI: angiotensin-converting-enzyme inhibitor.
ARB: angiotensin receptor blocker.